Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial.

Diabetes Obes Metab · 2022 · PMC9804559 · PMID 35837991

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

fell just short of statistical significanceP = .06so close (0.05 < p ≤ 0.1)

Treatment with empagliflozin was associated with an increase in LVEF that fell just short of statistical significance ( P = .06).

also in 125 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.